Details

Autor(en) / Beteiligte

• Li, Xiao-Lan
• Liu, Li-Peng
• Liu, Fang
• Guo, Ye
• Chen, Xiao-Juan
• Zhu, Xiao-Fan
• Yang, Wen-Yu

Titel

Safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia

Ist Teil von

• Zhongguo dang dai er ke za zhi, 2023-04, Vol.25 (4), p.374-380

Ort / Verlag

China

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• To study the safety and short-term effectiveness of blinatumomab in the treatment of childhood relapsed/refractory acute lymphoblastic leukemia (R/R-ALL). Six children with R/R-ALL who received blinatumomab treatment from August 2021 to August 2022 were included as subjects, and a retrospective analysis was performed for their clinical data. Among the six children, there were three boys and three girls, with a median age of 10.5 (5.0-13.0) years at the time of inclusion. Of all six children, one had refractory ALL and did not achieve remission after several times of chemotherapy, and 5 relapsed for the first time, with a median time of 30 (9-60) months from diagnosis to relapse. Minimal residual disease (MRD) before treatment was 15.50% (0.08%-78.30%). Three children achieved complete remission after treatment, among whom two had negative conversion of MRD. Five children had cytokine release syndrome (CRS), among whom 3 had grade 1 CRS and 2 had grade 2 CRS. Four children were bridged to allogeneic hematopoie